sur Medicure, Inc. (NASDAQ:MCUJF)
Medicure's Q3 2026 Financial Results Show Revenue Decline
Medicure Inc. reported its financial results for the quarter ended September 30, 2026. The company's net revenue reached $7.9 million, slightly down from $8.2 million in Q3 2025. ZYPITAMAG® sales remained stable at $1.7 million, with AGGRASTAT® sales dipping to $979,000 from $1 million in the same quarter the previous year.
The pharmacy business segment, including Marley Drug and two acquired pharmacies, posted revenues of $6.1 million, a decrease from $6.4 million in Q3 2025. Despite a $676,000 investment in R&D, which is less than the $717,000 from the previous year, the adjusted EBITDA showed a deeper loss at negative $820,000 compared to negative $597,000 in Q3 2025. The net loss was $1.3 million, consistent with last year's $1.4 million loss for the same period.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Medicure, Inc.